Drug Cos.
Hit Back In High Court 'Blocking Patent' Fight
A group of generic-drug makers pushed the U.S. Supreme Court
on Friday to uphold the so-called “blocking patent” doctrine that was used to strike
down multiple Acorda Therapeutics patents for multiple sclerosis drug Ampyra,
opening the door for companies to launch generic versions of the medication….
InvaGen
Agrees To Admit Infringing Diabetes Drug To End Suit
Pharmaceutical companies Mitsubishi Tanabe Pharma Corp.,
Janssen Pharmaceuticals Inc. and Cilag GmbH International have asked a New
Jersey federal judge to sign off on their deal to drop a patent infringement
lawsuit against InvaGen Pharmaceuticals Inc. over its application for the
generic version of Janssen's diabetes treatment Invokamet…
https://www.law360.com/articles/1166738/invagen-agrees-to-admit-infringing-diabetes-drug-to-end-suit
Fumarate and phosphate: Same same,
but different?
This case is about an alleged infringement of Gilead’s SPC
C00915894; the basic patent is EP 0 915 894 B1 (see EPO Register and Swissreg).
Gilead’s products are Truvada® and Atripla® which are pharmaceuticals for the
treatment of HIV-1 infection…
DE – Federal Court Of Justice
Confirms Rejection Preliminary Compulsory License Cholesterol Lowering Drugs
In its decision of 4 June 2019, the tenth senate of the
Federal Court of Justice (FCJ) confirmed a rejection of an application for a
preliminary compulsory license for a cholesterol-lowering drug. It is just the
second time that the FCJ had to deal with the questions of a compulsory
licence. The first case concerning an HIV Drug dates from July 2017. In that
decision from 2017 the FCJ granted a compulsory licence. Now the FCJ has
rejected such a compulsory licence as the facts of the cases differ…
A Functionally Claimed One-Step
Method
Eli Lilly and Company v. Erfindergemeinschaft UroPep GbR,
SCT Docket No. 18-1515 (Supreme Court 2019)
Lilly’s new petition for writ of certiorari asks an easy
question:
“Whether a single-step
patent claim that describes its point of novelty solely in functional terms
violates the rule against functional claiming set forth in Halliburton Oil Well
Cementing Co. v. Walker, 329 U.S. 1 (1946)”…
No comments:
Post a Comment